P2X7受体:慢性呼吸道疾病的潜在治疗点
Ping Huang1, Xichen Pang1, Xiaoju Liu2,3
1The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, China.
Molecular and cellular biochemistry
|October 16, 2025
概括
纯能带导离子通道7受体 (P2X7R) 影响慢性呼吸道疾病. 向P2X7R提供了潜在的治疗策略,但其双重作用,特别是在肺癌中,需要仔细考虑.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 纯能连接体带离子通道7受体 (P2X7R) 被细胞外腺三酸盐激活.
- P2X7R调节炎症反应,氧化应激,细胞死亡和免疫功能.
- 它与喘,COPD和肺癌等慢性呼吸道疾病的发病有关.
研究的目的:
- 审查P2X7R在慢性呼吸道疾病中的结构,功能和作用.
- 探索P2X7R参与这些条件的基础分子机制.
- 讨论P2X7R抗剂的临床应用.
主要方法:
- 综合文献综述. 这是一个全面的文献综述.
- 分析P2X7R的结构和功能.
- 探索P2X7R在各种呼吸道病理中的作用.
- 对P2X7R抗剂应用的审查.
主要成果:
- P2X7R调解离子流 (Na+,Ca2+流入,K+流出),影响细胞信号传输.
- P2X7R显著与喘,COPD,肺纤维化,肺癌,肺动脉高血压和结核病有关.
- P2X7R对抗剂显示出潜在的治疗应用,但它们的双重作用需要进一步研究.
结论:
- P2X7R是慢性呼吸道疾病病理生理学的关键参与者.
- 准P2X7R是一个有前途的治疗途径,用于呼吸系统疾病.
- 由于P2X7R的双重作用,特别是在肺癌中,需要谨慎的治疗策略.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.1K
Drugs Used in Lower Respiratory Disorders: Overview
995
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
995
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Chronic Obstructive Pulmonary Disease
2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K
COPD: Pathogenesis and Clinical Features
1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430


